Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Veracyte (NASDAQ:VCYT) but lowered the price target from $37 to $32.

October 20, 2023 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Veracyte but lowered the price target from $37 to $32.
The news is directly related to Veracyte and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the short-term value of the stock. However, the overall impact is neutral as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100